In April 2018, Linuo Pharma and Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. signed a strategic cooperation agreement on dr
In April 2018 , Linuo Pharma and Beijing Sun-Novo Pharmaceutical Research Co. ,Ltd. signed a strategic cooperation agreement on drug R&D in Beijing. The two sides have fully cooperated in technical consultation, commissioned R&D, joint R&D, and listing license holders. Nine products were screened and initially identified for the central nervous system, cardio-cerebrovascular and hypoglycemic drugs.
Beijing Sun-Novo is a national high-tech enterprise which integrates generic pharmacy and clinical research, raw materials and preparations . It has passed the ISO 9001:2008 quality management system certification. It is the first-class generic pharmaceutical R&D enterprise in Beijing and scientific and technological research and development institutions.
In June 2018 , the two sides identified 9 generic drug development contracts to start the research and development of generic drugs . Beijing Sun-Novo and the 2 generic drugs listed on the market are officially settled in 2019.
In order to sum up the work experience in 2017